Use of digoxigenin-labeled RNA probe to test hepatitis A virus antiviral drugs.
A nucleic acid hybridization assay was used to evaluate inhibitory activity of antiviral compounds against hepatitis A virus (HAV) in cell culture and compared to radioimmunoassay by analysis of variance procedure. The 5' genomic end of the HM-175 strain was used as digoxigenin-labeled RNA probe. Dot-blot examination showed a reduction of detectable HAV RNA in infected cells when treated with amphotericin B. An antiviral dose-effect was shown by statistical analysis of densitometric measures of hybridization signals. Comparison between molecular hybridization assay and radioimmunoassay by analysis of variance procedure showed the equivalence of both methods. Data previously obtained on selected drugs by antigen and infectious titres determinations were confirmed by hybridization assay and make possible digoxigenin-labeled RNA probe use to measure an antiviral dose-effect for screening of hepatitis A antiviral compounds.
Unité de Biologie Moléculaire, CRSSA, La Tronche, France.
H V
HV
Cuyck-Gandré
A
A
Job
M F
MF
Burckhart
S
S
Girond
J M
JM
Crance
D000577:Amides; D000666:Amphotericin B / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D002351:Carrageenan / Q000494:pharmacology; D004076:Digoxigenin / Q000494:pharmacology*; D006034:Glycyrrhetinic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D019695:Glycyrrhizic Acid; D017957:Hepatitis A Virus, Human / Q000187:drug effects*; D066298:In Vitro Techniques; D009693:Nucleic Acid Hybridization; D011720:Pyrazoles; D015347:RNA Probes / Q000187:drug effects*; D011863:Radioimmunoassay; D012263:Ribonucleosides / Q000494:pharmacology; D012266:Ribose
D000577:Amides; D000998:Antiviral Agents; D011720:Pyrazoles; D015347:RNA Probes; D012263:Ribonucleosides; C002997:pyrazofurin; D012266:Ribose; D019695:Glycyrrhizic Acid; D000666:Amphotericin B; D002351:Carrageenan; D004076:Digoxigenin; D006034:Glycyrrhetinic Acid